Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hanker, Lars
NCT05126342: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	Not yet recruiting	2	100	NA	Niraparib, Zejula, Dostarlimab, TSR-042	AGO Research GmbH, GlaxoSmithKline	Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer	11/24	11/26
SENTICOL III, NCT03386734: International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer	Active, not recruiting	N/A	989	Europe, Canada, Japan, RoW	SLN biopsy only, SLN biopsy + PLN dissection	Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT)	Cervical Cancer	05/27	05/29
CLAUS, Ellen
SENTICOL III, NCT03386734: International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer	Active, not recruiting	N/A	989	Europe, Canada, Japan, RoW	SLN biopsy only, SLN biopsy + PLN dissection	Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT)	Cervical Cancer	05/27	05/29